ClinicalTrials.gg
RecruitingNCT07038720Updated Nov 17, 2025

A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis

A Phase 1 interventional study of UA026 and Placebo in Plaque Psoriasis and Healthy Volunteer, sponsored by Usynova Pharmaceuticals Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Usynova Pharmaceuticals Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
111th of 182
124 · median 171
Started
2025
with 35 others
Phase 1
37 of 206
5 open now
Primary completion
2026-03
later than 17 of 65 live
Registered
161st of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 111th largest by planned enrollment of the 182 interventional ones that give a count, is one of 36 that started in 2025, is one of 37 in phase 1, reaches primary completion later than 17 of the 65 other live ones, and was the 161st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetic profile, and food effect of UA026 tablets.

The study consists of four parts: Part A is a single ascending dose (SAD) study, Part B is a multiple ascending dose (MAD) study, Part C is a food effect (FE) study, and Part D is a multi-dose parallel control study. Part A, B, and C will be conducted in healthy subject, and Part D will be conducted in subjects with moderate to severe plaque psoriasis.

Read the detailed description

Interleukin (IL)-17A is a proinflammatory cytokine that when dysregulated can lead to inflammatory disorders. Inhibiting IL-17A has shown remarkable clinical efficacy in psoriasis.UA026 is a high potency small molecule IL-17A inhibitor. This first-in-human study assessed the safety, tolerability, pharmacokinetics (PKs), and biomarkers including circulating IL-17A target engagement profile of single or multiple oral doses of the UA026 in healthy subject and subjects with moderate to severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis
  • Healthy Volunteer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

For Healthy Subject:

Inclusion Criteria

  1. Men and women aged 18-55 at the time of screening visit;
  2. (BMI) 18.5-28 kg/m2, inclusive, and total body weight ≥50 kg for male or ≥45 kg for female;
  3. Voluntarily participate in the study and provide the signed and dated ;
  4. For female subjects:

    1. With no , including those who has surgical sterilization (documented tubal ligation, hysterectomy, or bilateral oophorectomy) at least 6 weeks before the screening visit, and who menopause ≥12 months before the screening visit (confirmed by a follicle stimulating hormone (FSH) level ≥40IU/L), or
    2. With childbearing potential (WOCBP), must not be pregnant nor lactating, and must have used nonpharmacologic 30 days before administration, during the study, and for 3 months after dose, and must have tested negative for human chorionic gonadotropin (hCG) at the screening visit and D-1; female subjects must refrain from egg donation during this period.
  5. Males who are sexually active with WOCBP must have used nonpharmacologic contraception 14 days before administration, during the study, and for 3 months after administration. Male subjects must refrain from sperm donation during this time.
  6. Subject is willing to comply with protocol-specified visits, treatments, laboratory tests, and other study-related procedures and requirements.

Exclusion Criteria

  1. Allergy to the drugs or the , or a history of severe allergy (including any food allergy or drug allergy);
  2. Has received IL-17 small molecule inhibitors in the past;
  3. Medical history or family history of psychiatric disorders or genetic immunodeficiency;
  4. Has received hematopoietic stem cell transplantation, or organ transplantation in the past;
  5. History of chronic or recurrent infectious diseases, or systemic infection caused by fungal, parasitic or mycotic pathogens, or other opportunistic infections;
  6. History of active or latent tuberculosis (TB), or inadequately treated latent TB infection, or contact history of patients with TB;
  7. Has serious bone or joint infection within 6 months before screening, serious infection (e.g., hospitalization for infection or parenteral antibiotic treatment for infection), or herpes zoster virus infection within 3 months before screening;
  8. Positive surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab), or treponema pallidum antibody (TP-Ab);
  9. Subject with any acute infection, or any symptoms or signs of infection;
  10. Has presence of a surgical site, trauma site, severe mucosal ulceration, or incomplete fracture healing, or risk of gastrointestinal bleeding/perforation (e.g., active gastroduodenal ulcer, intestinal obstruction, ulcerative colitis, esophagogastric varices, gastrointestinal perforation within 6 months prior to screening), and risk of infection as assessed by the investigator;
  11. Abnormal liver function within 3 months prior to administration, or higher than the , AST, ALP, or TBL detected during screening period, and is ;
  12. Has abnormal coagulation parameters (including and international normalized ratio) and is clinically significant;
  13. Known or suspected history of drug abuse (e.g., morphine, methamphetamine, ketamine, dimethylene dioxyamphetamine, THC, cocaine, etc.), or positive at baseline screening for drug abuse;
  14. Alcohol abuse within 1 year prior to screening (drinking more than 14 standard units per week, with 1 standard unit containing 14g of alcohol, such as 360 ml of 5% beer, 45ml of 40% liquor, 120 ml of 12% wine), or positive breath test for alcohol during screening/baseline period;
  15. Smokes more than 5 cigarettes per day or the equivalent of 5 cigarettes per day of nicotine-containing products within 3 months before screening, or inability to comply with the smoking ban during the study;
  16. Has received vaccines within 3 months prior to screening, or plan to receive vaccines during the study;
  17. Has received any experimental drug or participated in any drug/investigational device trial within 3 months before dosing;
  18. Has undergone any surgery in the 3 months prior to screening, or planned to undergo surgery during the study period;
  19. Subject with previous severe or current chronic diseases of the central nervous system, cardiovascular, liver, kidney, lung, digestive tract, metabolic, hematological, skeletal, immune and other systems of clinical significance, or any other diseases or medical conditions that may affect the study or pose an unacceptable risk to the subject in the judgment of the investigator;
  20. History of abdominal surgery affecting the structure and function of the digestive tract;
  21. Subject with structural abnormalities of the digestive tract, or previous history of gastrointestinal disease (such as gastrointestinal bleeding, gastrointestinal perforation, gastroesophageal reflux disease, and inflammatory bowel disease) or current clinically significant gastrointestinal disease (such as gallstones) or symptoms (such as nausea, vomiting, and diarrhea), or patients who had undergone gastrointestinal surgery;
  22. Subject with symptoms of uninduced diarrhea within 3 months prior to screening;
  23. Any clinically significant abnormal results in vital signs, physical examination, or protocol-specified laboratory tests;
  24. Any clinically significant abnormal result in 12-lead ECGs, such as interval (Fridericia correction) > 450 ms for males and > 470 ms for females;
  25. Serum (Ccr) \< 90 mL/min, calculated according to Cockcroft-Gault formula: Creatinine clearance (mL/min) =(140-age) × body weight (kg) ×(0.85 [women only])/ 72 × serum creatinine (mg/dL), Or creatinine clearance (mL/min) =(140-age) × body weight (kg) ×(0.85 [women only])/ 0.81 × serum creatinine (μmol/L);
  26. Has received any drugs that may interact with the investigational drug within 7 days before administration, such as inhibitors and inducers, or P-gp inhibitors (refer to Appendix 12.6 for details);
  27. Has received any drugs that inhibit or induce hepatic drug-metabolizing enzymes within 7 days before screening; Ingestion of foods or beverages that induce or inhibit liver metabolism enzymes (e.g., grapefruit, etc.) within 48 hours before administration; Inability to comply with the prohibition of ingestion of any foods or beverages containing or metabolically producing caffeine or xanthine (e.g., coffee, tea, chocolate) within 48 hours before the first administration until the completion of the last PK blood sample;
  28. Inability to comply with the prohibition of the use of any medications, other than those permitted by the investigator, including prescription and over-the-counter medications (excluding topical eye/nose drops and creams without systemic exposure risk), vitamins (excluding conventional vitamins), health supplements, or Chinese herbal medicine within 14 days or 5 half-lives (whichever is longer) before administration until the last visit.
  29. Has donated or lost ≥400 ml of blood within the 3 months prior to screening, or planned to donate blood during the study period;
  30. Inability to be venipunctured for blood collection and/or has a history of fainting blood and fainting needles; Subject with any other serious systemic diseases, significant laboratory or procedure abnormalities, or other reasons that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study.

For Psoriasis Patient:

Inclusion Criteria

  1. Men and women aged 18-70 at the time of screening visit;
  2. Body mass index (BMI) 18-35 kg/m2, inclusive, and total body weight ≥ 40 kg;
  3. Patients with plaque psoriasis who meet the following criteria during screening:

    1. Diagnosis of plaque psoriasis for at least 6 months before the first administration, and, in the opinion of the Investigator, have stable psoriasis with no significant progression or morphological changes.
    2. Psoriasis Area and Severity Index (PASI) score 12
    3. Static physician's global assessment (sPGA) ≥3
    4. Psoriatic plaques must cover 10% of body surface area (BSA)
    5. Deemed by Investigator to be eligible for phototherapy or systemic therapy
    6. Subject is willing to discontinue topical and/or systemic therapies other than the investigational drugs, with the exception of topical moisturizer and low-intensity topical used for salvage therapy.
  4. Voluntarily participate in the study and provide the signed and dated informed consent;
  5. For female subjects:

    1. With no childbearing potential, including those who has surgical sterilization (documented tubal ligation, hysterectomy, or bilateral oophorectomy) at least 6 weeks before the screening visit, and who menopause ≥12 months before the screening visit (confirmed by a follicle stimulating hormone (FSH) level ≥40IU/L), or
    2. With childbearing potential (WOCBP), must not be pregnant nor lactating, and must have used nonpharmacologic contraception 30 days before administration, during the study, and for 3 months after dose, and must have tested negative for human chorionic gonadotropin (hCG) at the screening visit and D-1; female subjects must refrain from egg donation during this period;
  6. Males who are sexually active with WOCBP must have used nonpharmacologic contraception 14 days before administration, during the study, and for 3 months after administration. Male subjects must refrain from sperm donation during this time;
  7. Subject is willing to comply with protocol-specified visits, treatments, laboratory tests, and other study-related procedures and requirements.

Exclusion Criteria

  1. Allergy to the investigational drugs or the excipients, or a history of severe allergy (including any food allergy or drug allergy);
  2. Has received IL-17 small molecule inhibitors in the past;
  3. Diagnosis of non-plaque psoriasis (guttate, inverse, pustular, erythrodermic);
  4. Diagnosis of or at risk for drug-induced psoriasis (including, but not limited to, new-onset psoriasis or exacerbation of psoriasis caused by β receptor blockers, calcium channel inhibitors, or lithium, and newly use of β receptor blockers or calcium channel inhibitors within 2 years prior to enrollment);
  5. Has or suspected to have other skin or systemic diseases other than psoriasis and psoriatic arthritis;
  6. History of lack of response to Ustekinumab, Guselkumab, Tildrakizumab, Secukinumab, Ixekizumab, or Brodalumab (any therapeutic agent targeted to IL-12, IL-17 or IL-23) at approved doses after at least 3 months of therapy;
  7. Has received Ustekinumab, Guselkumab, Tildrakizumab, Secukinumab, Ixekizumab, or Brodalumab (any therapeutic agent targeted to IL-12, IL-17 or IL-23) within 3 months of first administration of investigational drugs;
  8. Has received TNF-α inhibitor(s) (Etanercept, Infliximab, Adalimumab, or Sacituzumab) within 2 months of first administration of investigational drugs;
  9. Has received phototherapy or any systemic medications/treatments for psoriasis, (including, but not limited to, Chinese medicines, JAK inhibitors, PDE4 inhibitors, TYK2 inhibitors, methotrexate, cyclosporin, retinoids) within 1 month of the first administration;
  10. Has used topical medications/treatments for psoriasis (including, but not limited to, glucocorticoids, vitamin D derivatives, retinoids, calcineurin inhibitors, aryl hydrocarbon receptor agonists, combination preparation for external use, Chinese medicines, JAK inhibitors, PDE4 inhibitors) within 2 weeks of the first administration;
  11. Has received any other monoclonal antibodies that the Investigator determined could affect the evaluation of the investigational drugs. For example, has received natalizumab, efalizumab, or agents that modulate B cells or T cells (eg, alemtuzumab, abatacept, alefacept, or visilizumab) within 3 months of the first administration; or has received rituximab within 6 months of the first administration;
  12. Medical history or family history of psychiatric disorders or genetic immunodeficiency;
  13. Has received hematopoietic stem cell transplantation, or organ transplantation in the past;
  14. History of chronic or recurrent infectious diseases, or systemic infection caused by fungal, parasitic or mycotic pathogens, or other opportunistic infections;
  15. History of active or latent TB, or inadequately treated latent TB infection, or contact history of patients with TB;
  16. Has serious bone or joint infection within 6 months before screening, serious infection (e.g., hospitalization for infection or parenteral antibiotic treatment for infection), or herpes zoster virus infection within 3 months before screening;
  17. Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or treponema pallidum antibody (TP-Ab);
  18. Subject with any acute infection, or any symptoms or signs of infection;
  19. Has presence of a surgical site, trauma site, severe mucosal ulceration, or incomplete fracture healing, or risk of gastrointestinal bleeding/perforation (e.g., active gastroduodenal ulcer, intestinal obstruction, ulcerative colitis, esophagogastric varices, gastrointestinal perforation within 6 months prior to screening), and risk of infection as assessed by the Investigator;
  20. History of malignant tumor or lymphoproliferative disease within the previous 5 years (other than resected cutaneous basal cell or squamous cell carcinoma, or carcinoma in situ of cervix that has been treated with no evidence of recurrence within the previous 3 years);
  21. Class III or IV congestive heart failure by Criteria; Or has unstable cardiovascular disease, defined as a recent clinical deterioration (e.g., unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months;
  22. Absolute WBC count, lymphocyte count, or is below the lower limit of normal and is clinically significant;
  23. Abnormal liver function within 3 months before the first administration, or higher than the upper limit of normal ALT, AST, ALP, or TBL detected during screening period, and is clinically significant;
  24. Serum creatinine clearance (Ccr) \< 60 mL/min, calculated according to Cockcroft-Gault formula;
  25. Has abnormal coagulation parameters (including prothrombin time and international normalized ratio) and is clinically significant;
  26. Known or suspected history of drug abuse (e.g., morphine, methamphetamine, ketamine, dimethylene dioxyamphetamine, THC, cocaine, etc.), or positive at baseline screening for drug abuse;
  27. Alcohol abuse within 1 year prior to screening (drinking more than 14 standard units per week, with 1 standard unit containing 14g of alcohol, such as 360 ml of 5% beer, 45ml of 40% liquor, 120 ml of 12% wine), or positive breath test for alcohol during screening/baseline period;
  28. Smokes more than 5 cigarettes per day or the equivalent of 5 cigarettes per day of nicotine-containing products within 3 months before screening, or inability to comply with the smoking ban during the study;
  29. Has received vaccines within 3 months prior to screening, or plan to receive vaccines during the study;
  30. Has received an experimental antibody or biologic therapy within the previous 6 months, or received any other experimental therapy or new investigational agent within 30 days or 5 half-lives (whichever is longer) of any study medication administration;
  31. Has undergone any surgery in the 3 months prior to screening, or planned to undergo surgery during the study period;
  32. Has donated or lost ≥400 ml of blood within the 3 months prior to screening, or planned to donate blood during the study period;
  33. Inability to be venipunctured for blood collection and/or has a history of fainting blood and fainting needles;
  34. Subject with any other serious systemic diseases, significant laboratory or procedure abnormalities, or other reasons that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    UA026

    Part A: SAD in healthy subjects Part B: MAD in healthy subjects Part C: FE in healthy subjects Part D: Multiple dose study in psoriasis patients

    Drug: UA026

  • Placebo comparator
    Placebo

    Part A: SAD in healthy subjects Part B: MAD in healthy subjects Part D: Multiple dose study in psoriasis patients

    Drug: Placebo

Interventions

  • DrugUA026

    UA026 will be administered as tablet

  • DrugPlacebo

    Matching placebo will be administered as tablet

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events (AEs)

    Time frame: up to 56 days

  2. Number of participants with clinically significant changes from baseline in vital signs

    Time frame: up to 56 days

  3. Number of participants with clinically significant changes from baseline in clinical laboratory values

    Safety and tolerability outcome measures include, but are not limited to vital signs, physical examination, 12-lead ECGs, clinical laboratory tests, and adverse events.

    Time frame: up to 56 days

  4. Number of participants with clinically significant changes from baseline in physical examination

    Time frame: up to 56 days

  5. Number of participants with clinically significant changes from baseline in 12-lead electrocardiograms(ECGs)

    Time frame: up to 56 days

Secondary outcomes

  1. Area under the plasma concentration-time curve from time zero to end of dosing interval (AUCtau) for Parts A, B, C and D

    Time frame: up to 72 hours after the last dose

  2. Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for Parts A, B, C, and D

    Time frame: up to 72 hours after the last dose

  3. Maximum observed plasma concentration (Cmax) for Parts A, B, C and D

    Time frame: up to 72 hours after the last dose

  4. Time to maximum plasma concentration (Tmax) for Parts A, B, C and D

    Time frame: up to 72 hours after the last dose

  5. Apparent terminal elimination half-life (t½) for Parts A, B, C and D

    Time frame: up to 72 hours after the last dose

  6. Apparent systemic clearance (CL/F) for Parts A, B, and C

    Time frame: up to 72 hours after the last dose

  7. Apparent volume of distribution (Vz/F) for Parts A, B, and C

    Time frame: up to 72 hours after the last dose

  8. MRT(Mean Residence Time)for Parts A, B, C and D

    Time frame: up to 72 hours after the last dose

  9. Accumulation ratios (Rac) for Parts B and D

    Time frame: up to 72 hours after the last dose

  10. degree of fluctuation(DF)for Parts B and D

    Time frame: up to 72 hours after the last dose

  11. the change in serum IL-17A level from the baseline for Parts A, B and D

    Time frame: up to 72 hours after the last dose

  12. the changes in serum beta-defensin 2(BD-2) from the baseline for Part D

    Time frame: up to 72 hours after the last dose

  13. the changes in serum IL-19 level from the baseline for Part D

    Time frame: up to 72 hours after the last dose

  14. The percentage change in psoriasis area and severity index (PASI) score from the baseline for Part D

    Time frame: up to 56 days

  15. Number of Participants Achieving 50% Improvement from Baseline in PASI (PASI-50) Score for Part D

    Time frame: up to 56 days

  16. Number of Participants Achieving 75% Improvement from Baseline in PASI (PASI-75) Score

    Time frame: up to 56 days

  17. Number of Participants Achieving 90% Improvement from Baseline in PASI (PASI-90) Score

    Time frame: up to 56 days

  18. Number of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) for Part D

    Time frame: up to 56 days

  19. The change in sPGA score from the baseline for Part D

    Time frame: up to 56 days

  20. The change in body surface area(BSA) from the baseline for Part D

    Time frame: up to 56 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2026, 9 months after the start.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 9 months is close to that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2025
First posted
Jun 26, 2025
StartActual
May 8, 2025
Primary completionEst.
Mar 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07038720
Lead sponsor
Usynova Pharmaceuticals Ltd.
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
May 8, 2025
Primary completion
Mar 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Nov 17, 2025

Study contacts

Yang Zhang
Contact
yang_zhang@usynova.com
+86 13636393195

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion